190 related articles for article (PubMed ID: 31703244)
21. An update on familial nonmedullary thyroid cancer.
Ammar SA; Alobuia WM; Kebebew E
Endocrine; 2020 Jun; 68(3):502-507. PubMed ID: 32162184
[TBL] [Abstract][Full Text] [Related]
22. Identification of NID1 as a novel candidate susceptibility gene for familial non-medullary thyroid carcinoma using whole-exome sequencing.
de Mello LEB; Carneiro TNR; Araujo AN; Alves CX; Galante PAF; Buzatto VC; das Graças de Almeida M; Vermeulen-Serpa KM; de Lima Vale SH; José de Pinto Paiva F; Brandão-Neto J; Cerutti JM
Endocr Connect; 2022 Jan; 11(1):. PubMed ID: 34941562
[TBL] [Abstract][Full Text] [Related]
23. HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
Zhang T; Xing M
J Natl Cancer Inst; 2016 Jun; 108(6):djv415. PubMed ID: 26832773
[TBL] [Abstract][Full Text] [Related]
24. Novel Susceptibility Genes Drive Familial Non-Medullary Thyroid Cancer in a Large Consanguineous Kindred.
Majdalani P; Yoel U; Nasasra T; Fraenkel M; Haim A; Loewenthal N; Zarivach R; Hershkovitz E; Parvari R
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175943
[TBL] [Abstract][Full Text] [Related]
25. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series.
Alsanea O; Wada N; Ain K; Wong M; Taylor K; Ituarte PH; Treseler PA; Weier HU; Freimer N; Siperstein AE; Duh QY; Takami H; Clark OH
Surgery; 2000 Dec; 128(6):1043-50;discussion 1050-1. PubMed ID: 11114641
[TBL] [Abstract][Full Text] [Related]
26. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations.
Cavaco BM; Batista PF; Martins C; Banito A; do Rosário F; Limbert E; Sobrinho LG; Leite V
Endocr Relat Cancer; 2008 Mar; 15(1):207-15. PubMed ID: 18310288
[TBL] [Abstract][Full Text] [Related]
27. Chromosomal localization of mutated genes in non-syndromic familial thyroid cancer.
Jiang YJ; Xia Y; Han ZJ; Hu YX; Huang T
Front Oncol; 2024; 14():1286426. PubMed ID: 38571492
[TBL] [Abstract][Full Text] [Related]
28. C14orf93 (RTFC) is identified as a novel susceptibility gene for familial nonmedullary thyroid cancer.
Liu C; Yu Y; Yin G; Zhang J; Wen W; Ruan X; Li D; Zhang S; Cai W; Gao M; Chen L
Biochem Biophys Res Commun; 2017 Jan; 482(4):590-596. PubMed ID: 27864143
[TBL] [Abstract][Full Text] [Related]
29. Penetrance of a rare familial mutation predisposing to papillary thyroid cancer.
Saporito D; Brock P; Hampel H; Sipos J; Fernandez S; Liyanarachchi S; de la Chapelle A; Nagy R
Fam Cancer; 2018 Jul; 17(3):431-434. PubMed ID: 29027612
[TBL] [Abstract][Full Text] [Related]
30. Familial Non-Medullary Thyroid Cancer Represents an Independent Risk Factor for Increased Cancer Aggressiveness: A Retrospective Analysis of 74 Families.
Tavarelli M; Russo M; Terranova R; Scollo C; Spadaro A; Sapuppo G; Malandrino P; Masucci R; Squatrito S; Pellegriti G
Front Endocrinol (Lausanne); 2015; 6():117. PubMed ID: 26284028
[TBL] [Abstract][Full Text] [Related]
31. Results of Screening in Familial Non-Medullary Thyroid Cancer.
Klubo-Gwiezdzinska J; Yang L; Merkel R; Patel D; Nilubol N; Merino MJ; Skarulis M; Sadowski SM; Kebebew E
Thyroid; 2017 Aug; 27(8):1017-1024. PubMed ID: 28657510
[TBL] [Abstract][Full Text] [Related]
32. Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer.
Na KY; Kim RM; Song EM; Lee JH; Lee J; Soh EY
J Surg Oncol; 2012 Jan; 105(1):10-4. PubMed ID: 21826673
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis and Management of Hereditary Thyroid Cancer.
Bano G; Hodgson S
Recent Results Cancer Res; 2016; 205():29-44. PubMed ID: 27075347
[TBL] [Abstract][Full Text] [Related]
34. The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer.
Xing M
Clin Endocrinol (Oxf); 2005 Sep; 63(3):263-6. PubMed ID: 16117812
[TBL] [Abstract][Full Text] [Related]
35. A pathogenic variant in CHEK2 shows a founder effect in Portuguese Roma patients with thyroid cancer.
Pires C; Marques IJ; Dias D; Saramago A; Leite V; Cavaco BM
Endocrine; 2021 Sep; 73(3):588-597. PubMed ID: 33683595
[TBL] [Abstract][Full Text] [Related]
36. Familial non-medullary thyroid cancer: a matched-case control study.
Maxwell EL; Hall FT; Freeman JL
Laryngoscope; 2004 Dec; 114(12):2182-6. PubMed ID: 15564841
[TBL] [Abstract][Full Text] [Related]
37. Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer.
Gara SK; Jia L; Merino MJ; Agarwal SK; Zhang L; Cam M; Patel D; Kebebew E
N Engl J Med; 2015 Jul; 373(5):448-55. PubMed ID: 26222560
[TBL] [Abstract][Full Text] [Related]
38. A Greek family with a follicular variant of familial papillary thyroid carcinoma: TCO, MNG1, fPTC/PRN, and NMTC1 excluded as susceptibility loci.
Tsilchorozidou T; Vafiadou E; Yovos JG; Romeo G; McKay J; Lesueur F; Bonora E
Thyroid; 2005 Dec; 15(12):1349-54. PubMed ID: 16405407
[TBL] [Abstract][Full Text] [Related]
39. Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density single-nucleotide polymorphism genome-wide linkage analysis.
Cavaco BM; Batista PF; Sobrinho LG; Leite V
J Clin Endocrinol Metab; 2008 Nov; 93(11):4426-30. PubMed ID: 18765515
[TBL] [Abstract][Full Text] [Related]
40. Frequent and Rare HABP2 Variants Are Not Associated with Increased Susceptibility to Familial Nonmedullary Thyroid Carcinoma in the Spanish Population.
de Randamie R; Martos-Moreno GÁ; Lumbreras C; Chueca M; Donnay S; Luque M; Regojo RM; Mendiola M; Hardisson D; Argente J; Moreno JC
Horm Res Paediatr; 2018; 89(6):397-407. PubMed ID: 29895015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
